Publicacións en colaboración con investigadores/as de Royal Marsden Hospital (4)

2021

  1. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 12, pp. 2091-2108

  2. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)

    Lung Cancer, Vol. 155, pp. 68-77

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

2008

  1. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

    British Journal of Cancer, Vol. 98, Núm. 10, pp. 1608-1613